Zolmitriptan

Quality 0.50 · 2 views · Updated 2 months ago

Medication used in treatment of migraines

title: "Zolmitriptan" type: doc version: 1 created: 2026-02-28 author: "Wikipedia contributors" status: active scope: public tags: ["2-oxazolidinones", "5-ht1b-agonists", "5-ht1d-agonists", "5-ht1e-agonists", "5-ht1f-agonists", "antiaggressive-drugs", "dimethylamino-compounds", "drugs-developed-by-astrazeneca", "experimental-psychiatric-drugs", "n,n-dialkyltryptamines", "triptans"] description: "Medication used in treatment of migraines" topic_path: "general/2-oxazolidinones" source: "https://en.wikipedia.org/wiki/Zolmitriptan" license: "CC BY-SA 4.0" wikipedia_page_id: 0 wikipedia_revision_id: 0

::summary Medication used in treatment of migraines ::

| Watchedfields = verified | verifiedrevid = 477869605 | IUPAC_name = (S)-4-({3-[2-(Dimethylamino)ethyl]-1H-indol-5-yl}methyl)-1,3-oxazolidin-2-one | image = Zolmitriptan.svg | image_class = skin-invert-image | width = 250px | image2 = Zolmitriptan 3D BS.png | image_class2 = bg-transparent | width2 = 225px

| tradename = Zomig, others | Drugs.com = | MedlinePlus = a601129 | DailyMedID = Zolmitriptan | pregnancy_AU = B3 | routes_of_administration = By mouth, intranasal | class = Serotonin 5-HT1B, 5-HT1D, 5-HT1E, and 5-HT1F receptor agonist; Antimigraine agent; Triptan

| legal_AU = S4 | legal_AU_comment = /S3 | legal_CA = Rx-only | legal_CA_comment = | legal_US = Rx-only

| bioavailability = Oral: 40% | protein_bound = 25% | metabolism = Liver (CYP1A2-mediated, to active metabolite; also ) | metabolites = • N-Desmethylzolmitriptan • Zolmitriptan N-oxide • Indole acetic acid derivative | elimination_half-life = Zolmitriptan: 3hours N-Desmethylzolmitriptan: 3.5hours | excretion = Urine: ~65% Feces: ~30%

| CAS_number_Ref = | CAS_number = 139264-17-8 | ATC_prefix = N02 | ATC_suffix = CC03 | ATC_supplemental = | ATCvet = QN02CC03 | PubChem = 60857 | IUPHAR_ligand = 60 | DrugBank_Ref = | DrugBank = DB00315 | ChemSpiderID_Ref = | ChemSpiderID = 54844 | UNII_Ref = | UNII = 2FS66TH3YW | KEGG_Ref = | KEGG = D00415 | ChEBI_Ref = | ChEBI = 10124 | ChEMBL_Ref = | ChEMBL = 1185 | synonyms = BW-311C90; BW311C90; 311C90; BW-311-C-90; ML-004; ML004; [(4S)-2-Oxo-1,3-oxazolidin-4-yl]methyl-N,N-dimethyltryptamine; [(4S)-2-Oxo-1,3-oxazolidin-4-yl]methyl-DMT

| C=16 | H=21 | N=3 | O=2 | SMILES = O=C1OCC@@HCc2ccc3c(c2)c(c[nH]3)CCN(C)C | StdInChI_Ref = | StdInChI = 1S/C16H21N3O2/c1-19(2)6-5-12-9-17-15-4-3-11(8-14(12)15)7-13-10-21-16(20)18-13/h3-4,8-9,13,17H,5-7,10H2,1-2H3,(H,18,20)/t13-/m0/s1 | StdInChIKey_Ref = | StdInChIKey = ULSDMUVEXKOYBU-ZDUSSCGKSA-N Zolmitriptan, sold under the brand name Zomig among others, is a serotonergic medication which is used in the acute treatment of migraine attacks with or without aura and cluster headaches. It is taken by mouth as a swallowed or disintegrating tablet or as a nasal spray.

Side effects include tightness in the neck or throat, jaw pain, dizziness, paresthesia, asthenia, somnolence, warm/cold sensations, nausea, chest pressure, and dry mouth. The drug acts as a selective serotonin 5-HT1B and 5-HT1D receptor agonist. Structurally, it is a triptan and a tryptamine derivative.

It was patented in 1990 and was approved for medical use in 1997.

Medical uses

Migraine

Zolmitriptan is used for the acute treatment of migraines with or without aura in adults. It is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine.

Off-label uses

Available forms

Zolmitriptan is available as a swallowed tablet, an orally disintegrating tablet, and as a nasal spray, in doses of 2.5 and 5mg. People who get migraines from aspartame should not use the disintegrating tablet (Zomig ZMT) as it contains aspartame.

A 2014 Cochrane review has shown that zolmitriptan 5mg nasal spray was significantly more effective than the 5mg oral tablet.

Contraindications

Zolmitriptan is contraindicated in patients with cerebrovascular or cardiovascular disease because serotonin 5-HT1B receptors are present in coronary arteries. Such conditions include, but are not limited to, coronary artery disease, stroke, and peripheral vascular disease. It is also contraindicated in hemiplegic migraine.

Side effects

Side effects include neck/throat/jaw pain/tightness/pressure, dizziness, paresthesia, asthenia, somnolence, warm/cold sensations, nausea, heaviness sensation, and dry mouth.

As for cardiovascular side effects, zolmitriptan can increase systolic blood pressure in the elderly and increase diastolic blood pressure in both the elderly and young people. Additionally, there is the side effect of a dose-related increase in sedation. There is a risk for medication withdrawal headache or medication overuse headache.

Zolmitriptan has a weak affinity for serotonin 5-HT1A receptors; these receptors have been implicated in the development of serotonin syndrome.

Overdose

There is limited experience with overdose of zolmitriptan and there is no specific antidote for zolmitriptan overdose. A dose of zolmitriptan of 50mg, which is 10- to 40-fold the clinically used dose range of 1.25 to 5mg, commonly resulted in sedation in patients in a clinical study. Zolmitriptan has a relatively short elimination half-life of 3hours, and so symptoms of overdose may be expected to resolve within around 15hours post-intake.

Interactions

Following administration of the non-selective cytochrome P450 inhibitor cimetidine, the elimination half-life and total exposure of zolmitriptan and its active metabolite were approximately doubled. The major metabolite of zolmitriptan, N-desmethylzolmitriptan (183C91), which is active and has several-fold greater affinity for the serotonin 5-HT1B and 5-HT1D receptors than zolmitriptan, is metabolized into an inactive form by monoamine oxidase A (MAO-A). The reversible inhibitor of MAO-A (RIMA) moclobemide combined with zolmitriptan has been found to increase N-desmethylzolmitriptan exposure and peak levels by 1.5- to 3-fold.

Pharmacology

Pharmacodynamics

::data[format=table title="{{Nowrap|Zolmitriptan activities}}"]

TargetAffinity (Ki, nM)
5-HT1A16–316 (Ki)
3,020–10,000 ()
55% ()
5-HT1B0.47–20 (Ki)
3.8–60 (EC50)
99–102% (Emax)
5-HT1D0.11–4 (Ki)
0.29–1.6 (EC50)
86–106% (Emax)
5-HT1E10–10,000 (Ki)
6.6–62 (EC50)
101% (Emax)
5-HT1F28–617 (Ki)
10–420 (EC50)
97% (Emax)
5-HT2A10,000 (Ki)
10,000 (EC50)
5-HT2B65–10,000 (Ki)
10,000 (EC50)
5-HT2C79,400 (Ki) (guinea pig)
ND (EC50)
5-HT33,160 (mouse)
5-HT43,160 (guinea pig)
5-HT5A398 (rat)
5-HT63,160
5-HT787–96 (Ki)
525 (EC50)
α1A–α1DND
α279,000
α2A–α2CND
β1–β3ND
D1, D2100,000
D3–D5ND
H1–H4ND
M1–M5ND
I1, I2ND
σ1, σ2ND
ND
ND
ND
ND
Notes: The smaller the value, the more avidly the drug binds to the site. All proteins are human unless otherwise specified. Refs:
::

Zolmitriptan is a selective serotonin 5-HT1B and 5-HT1D receptor agonist with weak affinity for the serotonin 5-HT1A receptor. It also has affinity for other serotonin receptors, including the serotonin 5-HT1E, 5-HT1F, 5-HT2B, 5-HT5A, and 5-HT7 receptors. Conversely, its affinities for the serotonin 5-HT2A, 5-HT2C, 5-HT3, 5-HT4, and 5-HT6 receptors are negligible or undetectable. It is likewise inactive as a serotonin 5-HT2A receptor agonist.

Zolmitriptan's major metabolite, N-desmethylzolmitriptan (183C91), is also active and has about 2- to 6-fold the affinity of zolmitriptan for the serotonin 5-HT1B and 5-HT1D receptors.

Its action on serotonin 5-HT1B and 5-HT1D receptors causes vasoconstriction in intracranial blood vessels; as well it can inhibit the release of pro-inflammatory neuropeptides from trigeminal perivascular nerve endings. It crosses the blood–brain barrier as evidenced by the presence of radiolabeled zolmitriptan within the cells of the trigeminal nucleus caudalis and nucleus tractus solitarii.

Pharmacokinetics

Absorption

Zolmitriptan has a rapid onset of action and has been detected in the brain as early as within 5minutes of intranasal administration. On average, zolmitriptan has an oral bioavailability of 40%, a mean volume of distribution of 8.3L/kg after oral administration, and 2.4L/kg after intravenous administration.

Distribution

Zolmitriptan is a more lipophilic compound with greater central permeability than certain other triptans like sumatriptan. It has been found to cross the blood–brain barrier and enter the central nervous system both in animals and humans. In a clinical pharmacokinetic study, brain concentrations were about 20% of plasma concentrations. However, in another clinical study, the drug achieved relatively low occupancy of central serotonin 5-HT1B receptors (4–5%) as measured by positron emission tomography (PET) imaging.

Metabolism

Zolmitriptan is metabolized into three major metabolites by the human hepatic cytochrome P450 enzymes—primarily CYP1A2. Two-thirds of the parent compound breaks down into the active metabolite N-desmethylzolmitriptan (183C91), while the remaining one-third separates into the other two inactive metabolites: zolmitriptan N-oxide and an indole acetic acid derivative. N-Desmethylzolmitriptan circulates at higher levels than those of zolmitriptan. This metabolite is deaminated by monoamine oxidase A (MAO-A).

Elimination

Zolmitriptan has an elimination half-life of about 3hours before it undergoes renal elimination; its clearance is greater than the glomerular filtration rate suggesting that there is some renal tubular secretion of the compound.

Chemistry

Zolmitriptan, also known as [(4S)-2-oxo-1,3-oxazolidin-4-yl]methyl-N,N-dimethyltryptamine, is a tryptamine derivative and a 5-substituted derivative of the psychedelic drug dimethyltryptamine (DMT). It is specifically the derivative of DMT in which the hydrogen atom at position 5 of the indole ring has been substituted with a [(4S)-2-oxo-1,3-oxazolidin-4-yl]methyl group.

The experimental log P of zolmitriptan is 1.6 to 1.8. For comparison, the experimental log P of sumatriptan is 0.8 to 0.93. Zolmitriptan is much more lipophilic than sumatriptan.

Analogues of zolmitriptan include other triptans like sumatriptan, naratriptan, rizatriptan, eletriptan, almotriptan, and frovatriptan.

History

Zolmitriptan was patented in 1990 and was first described in the scientific literature by 1994. It was first introduced for medical use in the United States in 1997.

Society and culture

Brand names

Zolmitriptan is marketed by AstraZeneca with the brand names Zomig, Zomigon (Argentina, Canada, and Greece), AscoTop (Germany) and Zomigoro (France).

Economics

In 2008, Zomig generated nearly $154 million in sales.

AstraZeneca's U.S. patent on Zomig tablets expired on November 14, 2012, and its pediatric exclusivity extension expired on May 14, 2013. The patent in certain European countries has already expired too, and generic drug maker Actavis released a generic version in those countries, starting in March 2012.

Legal status

In Russia, versions of zolmitriptan which are not registered in the National registry of medications may be regarded as narcotic drugs (derivatives of dimethyltriptamine).

Research

Obsessive–compulsive disorder

Zolmitriptan showed no effect on obsessive–compulsive disorder (OCD) symptoms nor on mood or anxiety in a clinical study.

Social deficits and aggression

Zolmitriptan, in a modified-release formulation with code name ML-004 (or ML004), is under development by MapLight Therapeutics for the treatment of pervasive developmental disorders (e.g., autism), agitation, and aggression. The drug has been found to reduce aggression in rodents and has also been reported to decrease aggression in humans. As of June 2023, zolmitriptan is in phase 2 clinical trials for pervasive developmental disorders, phase 1 clinical trials for agitation, and is in the preclinical stage of development for aggression.

References

References

  1. (May 2025). "Therapeutic Goods (Poisons Standard— June 2025) Instrument 2025".
  2. (6 June 2024). "Product monograph brand safety updates".
  3. (25 November 1997). "Zolmitriptan: Uses, Interactions, Mechanism of Action".
  4. "Highlights of prescribing information".
  5. "Zolmitriptan".
  6. (2006). "Analogue-based Drug Discovery". John Wiley & Sons.
  7. (2020). "Zolmitriptan". Statpearls.
  8. (2001). "Migraine MLT-Down: An Unusual Presentation of Migraine in Patients With Aspartame-Triggered Headaches". Headache: The Journal of Head and Face Pain.
  9. (May 2014). "Zolmitriptan for acute migraine attacks in adults". Cochrane Database Syst Rev.
  10. "BindingDB BDBM50033383 (S)-4-((3-(2-(dimethylamino)ethyl)-1H-indol-5-yl)methyl)oxazolidin-2-one::(S)-4-[3-(2-Dimethylamino-ethyl)-1H-indol-5-ylmethyl]-oxazolidin-2-one::311C90::CHEMBL1185::ZOLMITRIPTAN::ZOMIG::ZOMIG-ZMT".
  11. (1999). "Pharmacology of triptans". Emerging Drugs.
  12. (December 2000). "Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy". Drugs.
  13. (July 2000). "Current and emerging second-generation triptans in acute migraine therapy: a comparative review". J Clin Pharmacol.
  14. (2001). "Success and failure of triptans". The Journal of Headache and Pain.
  15. (22 December 1999). "Coronary Side Effects of Antimigraine Drugs From Patient to Receptor".
  16. (13 March 2002). "Vascular Effects of Antimigraine Drugs: pharmacology of human in vitro models in migraine".
  17. (May 1997). "Receptor specificity and trigemino-vascular inhibitory actions of a novel 5-HT1B/1D receptor partial agonist, 311C90 (zolmitriptan)". British Journal of Pharmacology.
  18. (1997). "How efficacious are 5-HT1B/D receptor ligands: an answer from GTP gamma S binding studies with stably transfected C6-glial cell lines". Neuropharmacology.
  19. (September 1995). "Computer-aided design and synthesis of 5-substituted tryptamines and their pharmacology at the 5-HT1D receptor: discovery of compounds with potential anti-migraine properties". Journal of Medicinal Chemistry.
  20. (September 1995). "Synthesis and serotonergic activity of arylpiperazide derivatives of serotonin: potent agonists for 5-HT1D receptors". Journal of Medicinal Chemistry.
  21. (March 1998). "Dimerization of sumatriptan as an efficient way to design a potent, centrally and orally active 5-HT1B agonist". Bioorganic & Medicinal Chemistry Letters.
  22. (October 2010). "Preclinical pharmacological profile of the selective 5-HT1F receptor agonist lasmiditan". Cephalalgia.
  23. (December 2019). "Characterization of binding, functional activity, and contractile responses of the selective 5-HT1F receptor agonist lasmiditan". British Journal of Pharmacology.
  24. Perez, M.. (1999). "F-11356". Drugs of the Future.
  25. (2012). "Lasmiditan hydrochloride". Drugs of the Future.
  26. (2024). "Migraine Management".
  27. (April 2002). "Pharmacology of the selective 5-HT(1B/1D) agonist frovatriptan". Headache.
  28. (June 2008). "Indolealkylamines: biotransformations and potential drug-drug interactions". AAPS J.
  29. (November 1998). "The absolute bioavailability and effect of food on the pharmacokinetics of zolmitriptan in healthy volunteers". British Journal of Clinical Pharmacology.
  30. (October 1997). "Pre-clinical pharmacology of zolmitriptan (Zomig; formerly 311C90), a centrally and peripherally acting 5HT1B/1D agonist for migraine". Cephalalgia.
  31. (August 2012). "Pharmacokinetic evaluation of zolmitriptan for the treatment of migraines". Expert Opin Drug Metab Toxicol.
  32. (March 2017). "Serotonergic mechanisms in the migraine brain - a systematic review". Cephalalgia.
  33. (July 2013). "A PET study with [11C]AZ10419369 to determine brain 5-HT1B receptor occupancy of zolmitriptan in healthy male volunteers". Cephalalgia.
  34. (2005). "Distribution of zolmitriptan into the CNS in healthy volunteers: a positron emission tomography study". Drugs in R&D.
  35. (2013). "Medicinal chemistry of antimigraine drugs". Curr Med Chem.
  36. "Sumatriptan".
  37. (1994). "Joint 1994 Wolff Award Presentation. Peripheral and central trigeminovascular activation in cat is blocked by the serotonin (5HT)-1D receptor agonist 311C90". Headache.
  38. (1994). "Pre-clinical profile of the novel 5-HT 1D receptor agonist 311C90.". New Advances in Headache Research.
  39. (1994). "Clinical pharmacology of 311C90.". New Advances in Headache Research.
  40. (5 November 2023). "AstraZeneca/Burroughs Wellcome".
  41. "2008 Top 200 generic drugs by retail dollars".
  42. "Generic Zomig-ZMT Availability".
  43. "Migraine treatment Zolmitriptan launched by Actavis in Europe".
  44. "Постановление Правительства РФ от 30 июня 1998 г. N 681 "Об утверждении перечня наркотических средств, психотропных веществ и их прекурсоров, подлежащих контролю в Российской Федерации" (с изменениями и дополнениями)". [[Гарант (справочно-правовая система).
  45. (May 2018). "The 5-HT1B receptor - a potential target for antidepressant treatment". Psychopharmacology (Berl).
  46. (September 2000). "Zolmitriptan (a 5-HT1B/1D receptor agonist with central action) does not increase symptoms in obsessive compulsive disorder". Psychopharmacology (Berl).
  47. (8 June 2023). "ML 004".
  48. (28 September 2024). "Delving into the Latest Updates on ML-004 with Synapse".
  49. (28 April 2023). "Going on Trial: Serotonin drug; psilocybin phase 2; placebo response data".
  50. (August 2024). "TAAR1 and 5-HT1B receptor agonists attenuate autism-like irritability and aggression in rats prenatally exposed to valproic acid". Pharmacol Biochem Behav.
  51. "Maplight Autism Study".
  52. "Zolmitriptan by MapLight therapeutics for Autism Spectrum Disorder (ASD): Likelihood of Approval".
  53. (January 2008). "Drugs and aggression". Recent Pat CNS Drug Discov.
  54. (December 2005). "5-HT1A and 5-HT1B receptor agonists and aggression: a pharmacological challenge of the serotonin deficiency hypothesis". Eur J Pharmacol.
  55. (September 2001). "Zolmitriptan--a 5-HT1B/D agonist, alcohol, and aggression in mice". Psychopharmacology (Berl).
  56. (June 2021). "Time to re-engage psychiatric drug discovery by strengthening confidence in preclinical psychopharmacology". Psychopharmacology (Berl).
  57. (July 2010). "Zolmitriptan and human aggression: interaction with alcohol". Psychopharmacology (Berl).

::callout[type=info title="Wikipedia Source"] This article was imported from Wikipedia and is available under the Creative Commons Attribution-ShareAlike 4.0 License. Content has been adapted to SurfDoc format. Original contributors can be found on the article history page. ::

2-oxazolidinones5-ht1b-agonists5-ht1d-agonists5-ht1e-agonists5-ht1f-agonistsantiaggressive-drugsdimethylamino-compoundsdrugs-developed-by-astrazenecaexperimental-psychiatric-drugsn,n-dialkyltryptaminestriptans